What Happened
- A new study published in Science Translational Medicine confirms that while HIV can develop resistance to lenacapavir — the first-in-class HIV capsid inhibitor — doing so comes at a severe fitness cost to the virus.
- Resistance mutations (principally M66I) allow HIV to evade lenacapavir's binding to the capsid protein, but simultaneously reduce the virus's replication capacity to as low as 17% of normal HIV.
- Compensatory mutations (N74D and A105T) can partially restore viral fitness to 34%, but high-level resistance and high fitness cannot be simultaneously achieved — the capsid's structure is too important for the virus to tolerate large alterations.
- The finding confirms that the HIV capsid is a robust and valid drug target: to escape the drug, the virus must damage its own critical machinery.
- Lenacapavir (brand name: Sunlenca) — developed by Gilead Sciences — is already approved in the US, EU, and several other countries for heavily treatment-experienced (HTE) adults with multidrug-resistant HIV.
- Zimbabwe became one of the first countries to roll out lenacapavir programmatically in early 2026, reflecting growing global interest in this class of drugs.
Static Topic Bridges
HIV Capsid — Structure, Function, and Drug Target
The HIV capsid is a cone-shaped protein shell made of approximately 1,500 copies of the HIV CA (capsid) protein. It encloses and protects the viral RNA genome and key enzymes (reverse transcriptase, integrase) during the early stages of infection. The capsid performs multiple critical functions in the HIV replication cycle: it facilitates nuclear import of the viral genome into host cells, participates in reverse transcription, and ensures the viral genome reaches the host cell nucleus intact.
- The capsid's structural integrity is non-negotiable for viral replication — any mutation that disrupts it significantly reduces viral fitness
- Lenacapavir binds at a specific pocket (the NTD-CTD interface) in the capsid protein hexamers, disrupting capsid assembly and disassembly at multiple stages of the viral life cycle
- The M66I resistance mutation rearranges the lenacapavir binding pocket, reducing drug binding — but also structurally weakens the capsid, reducing replication to ~17%
- Compensatory mutations (N74D, A105T) partially restore capsid function but cannot fully offset the fitness penalty
- The HIV capsid was long considered "undruggable" because of the precision required to bind it without harming the host — lenacapavir's success disproved this
Connection to this news: The study's key finding is that the capsid is structurally constrained — it cannot mutate to resist lenacapavir without simultaneously impaying its own function. This "target vulnerability" makes the HIV capsid one of the most promising long-term drug targets in antiviral medicine.
Lenacapavir — Drug Profile and Mechanism
Lenacapavir (brand: Sunlenca; developer: Gilead Sciences) is a first-in-class HIV capsid inhibitor, representing the first entirely new drug class for HIV treatment in over two decades. It is a long-acting injectable: a single subcutaneous injection provides therapeutic drug levels for six months, addressing the challenge of daily pill adherence. It targets the HIV capsid protein at multiple points in the replication cycle — before, during, and after nuclear import.
- Class: Capsid inhibitor (CpAM — Capsid Protein Allosteric Modulator)
- Route: Subcutaneous injection every 6 months (in treatment) — one of the longest-acting HIV drugs available
- Approvals: US FDA (August 2022), EMA (European Medicines Agency, August 2022); approved for heavily treatment-experienced (HTE) adults with multidrug-resistant HIV
- In the PURPOSE 1 and PURPOSE 2 trials (prevention): lenacapavir as PrEP (pre-exposure prophylaxis) showed 100% and 96% efficacy respectively in preventing HIV acquisition — a landmark result announced in 2024-2025
- Gilead has committed to tiered pricing and generic licensing agreements to enable lenacapavir access in low- and middle-income countries for PrEP use
- Mechanism: Interferes with capsid assembly (before virus budding), capsid disassembly (after cell entry), nuclear transport of the viral genome, and potentially reverse transcription
Connection to this news: The resistance study confirms that lenacapavir's mechanism — binding a structurally critical viral protein — means resistance is possible but costly. This is more favourable than resistance to drugs like NRTIs (nucleoside reverse transcriptase inhibitors), where resistance mutations impose less fitness cost.
HIV Drug Resistance and Treatment Landscape
HIV's high mutation rate (approximately 10^-5 per base per replication cycle) means the virus continually generates diverse variants. Drug resistance arises when mutations that confer resistance are selected because they allow the virus to replicate in the presence of the drug. Managing resistance is central to long-term HIV treatment success and has driven the development of combination antiretroviral therapy (ART).
- Current ART standard: three-drug combinations (two NRTIs + one integrase strand transfer inhibitor, INSTI, like dolutegravir) minimise resistance emergence by attacking multiple viral targets simultaneously
- Dolutegravir-based regimens have an extremely high resistance barrier — making them the global first-line treatment standard (WHO guidelines)
- Heavily treatment-experienced (HTE) patients: those who have developed resistance to drugs from multiple classes; a small but medically critical population for whom lenacapavir was initially approved
- Three main lenacapavir resistance mutations: M66I (high resistance, extreme fitness cost), Q67H, and others that emerge more slowly
- The combination of high resistance barrier + fitness cost makes lenacapavir attractive for long-acting PrEP (where the drug is used in HIV-negative people, so resistance from treatment failure is not a concern)
Connection to this news: The study's findings are directly relevant to how lenacapavir will be deployed clinically and epidemiologically. For treatment (HTE patients), the high fitness cost of resistance means resistant viruses are less likely to spread. For PrEP, resistance in HIV-negative individuals is essentially moot — confirming lenacapavir as a highly suitable PrEP agent.
HIV/AIDS — Global and India Burden
HIV (Human Immunodeficiency Virus) causes AIDS (Acquired Immunodeficiency Syndrome) by progressively destroying CD4+ T lymphocytes (immune cells), leaving the body vulnerable to opportunistic infections and cancers. Globally, approximately 39.9 million people live with HIV (UNAIDS 2024). India has an estimated 2.4 million people living with HIV — the third-largest burden globally — with an adult HIV prevalence of approximately 0.22%.
- Global: 39.9 million people living with HIV (PLHIV) — 2024 UNAIDS data
- Annual new HIV infections globally: ~1.3 million in 2023 (target: <370,000 by 2025 — "95-95-95" strategy)
- India: ~2.4 million PLHIV; adult prevalence ~0.22% (below the global average of ~0.7%)
- India's National AIDS Control Organisation (NACO) under Ministry of Health runs the National AIDS Control Programme (NACP)
- UNAIDS 95-95-95 target: 95% of PLHIV know their status; 95% of diagnosed on treatment; 95% on treatment virally suppressed — India has made substantial progress
- Antiretroviral therapy (ART) suppresses the virus to undetectable levels, making HIV a manageable chronic condition and preventing transmission ("Undetectable = Untransmittable" or U=U)
Connection to this news: India is not yet using lenacapavir programmatically, but the drug's potential as a six-monthly PrEP agent (following PURPOSE trials) has significant implications for India's HIV prevention strategy, particularly for high-risk populations. The resistance study provides reassurance about the drug's long-term viability as a treatment and prevention tool.
Key Facts & Data
- Lenacapavir (Sunlenca): first-in-class HIV capsid inhibitor; subcutaneous injection every 6 months
- Developer: Gilead Sciences; FDA approval: August 2022; EMA approval: August 2022
- Mechanism: Targets HIV capsid at multiple replication cycle stages (assembly, disassembly, nuclear transport)
- Resistance study: published in Science Translational Medicine (2026); key finding — HIV can develop resistance but at severe fitness cost
- M66I mutation: high-level resistance to lenacapavir, but reduces viral replication capacity to ~17% of normal
- Compensatory mutations (N74D + A105T): partially restore replication to ~34%, but cannot achieve high fitness + high resistance simultaneously
- PURPOSE 1 trial (sub-Saharan African women): 100% efficacy as PrEP
- PURPOSE 2 trial (men who have sex with men, transgender persons, other populations): 96% efficacy as PrEP
- Zimbabwe: among first countries to roll out lenacapavir programmatically (early 2026)
- Global PLHIV: ~39.9 million (UNAIDS 2024); India: ~2.4 million (third largest burden)
- India HIV prevalence: ~0.22% (adult); managed by NACO under National AIDS Control Programme
- Gilead has agreed to generic licensing for lenacapavir PrEP in low- and middle-income countries